Encora Therapeutics
Encora Therapeutics develops the Encora X1, an FDA-cleared non-invasive wrist-worn neurostimulation device that uses AI-powered closed-loop technology to deliver personalized tremor relief for adults with essential tremor in the United States.
- Company typePrivate
- Founded2018
- HeadquartersBoston, United States
- Headcount1–10
- GTM typeB2C
- OfferingHardware or Manufacturing
What Encora Therapeutics does
Encora Therapeutics is a clinical-stage medical device company that developed the Encora X1, an FDA 510(k)-cleared, non-invasive wrist-worn neurostimulation device indicated to aid in the relief of hand tremors in adults with essential tremor. The device uses an AI-powered closed-loop system that analyzes physiological tremor signals in real time and delivers personalized mechanical stimulation to the wrist, functioning as a non-surgical, drug-free alternative to beta-blockers, anticonvulsants, and deep brain stimulation. Founded in 2018 and headquartered in Boston, MA, the company employed fewer than 10 people and operated a prescription-only distribution model routed through physicians, with a website-based patient waitlist used to capture and stage demand by geography. The product is indicated and marketed solely in the United States, and in clinical trials device-related adverse events were reported as non-serious and self-resolving.
The company was venture-backed through small rounds (including $1.5M led by Innospark Ventures in 2020 and $200K led by Good Growth Capital) before being acquired by Coforge, an Indian IT services provider listed on the NSE, in April 2026 for approximately $2.35 billion. The acquisition was reported as one of India's largest outbound M&A transactions in Q1 2026. Encora now operates as a wholly-owned subsidiary of Coforge, intended to extend the parent's capabilities into AI-driven medtech. Pre-acquisition leadership included a CEO transition in October 2025, with Nadim Yared appointed Chairman and CEO and co-founder Daniel Carballo moving into a strategy role. Encora's core technical asset is its proprietary closed-loop neurostimulation platform, which the company has indicated is applicable in principle to additional movement-disorder indications beyond essential tremor.
Encora Therapeutics firmographics
Firmographics- Name
- Encora Therapeutics
- Legal name
- Encora Therapeutics
- Website
- https://encoratherapeutics.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Acquired
- Headcount range
- 1–10 employees
- Short description
- Encora Therapeutics develops the Encora X1, an FDA-cleared non-invasive wrist-worn neurostimulation device that uses AI-powered closed-loop technology to deliver personalized tremor relief for adults with essential tremor in the United States.
- Ownership category
- akta.pro rank
Encora Therapeutics industry classification
Industry- Product category
- Wearable Neurostimulation Medical Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables) (HLAHACAE)
- akta.pro secondary industry
- Rehabilitation Therapy Equipment (PT/OT Modalities, Exercise & Balance Devices) (HLAHAMAG)
Keywords
Where Encora Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Boston
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Encora Therapeutics business model
Business model- GTM type
- B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales
Revenue model
- Encora X1 Device Sales: Revenue generated from the sale of the Encora X1 neurostimulation wearable device. The device is available by prescription only and sold through or on the order of a physician. As a medical device, this is a one-time hardware sale model with potential for accessories and replacement parts.
Distribution channels1 record
Marketing channels6 records
Encora Therapeutics product offering
Product offeringCore offering
Encora Therapeutics develops and sells the Encora X1, an FDA 510(k)-cleared, non-invasive, wrist-worn wearable neurostimulation device indicated to aid in the relief of hand tremors in adults with essential tremor. The device uses proprietary AI-powered closed-loop technology to perform real-time tremor signal analysis and deliver personalized mechanical stimulation for tremor relief, and is available by prescription only through physician channels in the United States.
Product overview
Encora Therapeutics offers a single core product: the Encora X1, an FDA 510(k)-cleared wearable neurostimulation device designed for treating essential tremor in adults. The device is a prescription-only, non-invasive wrist-worn therapeutic stimulation system that leverages AI-powered closed-loop technology to analyze tremor patterns and deliver personalized mechanical stimulation for tremor relief.
Differentiator
Problem solved
Functional benefit
Products and services
- Encora X1 FDA 510(k)-cleared, prescription-only, non-invasive, wrist-worn wearable neurostimulation device that uses AI-powered closed-loop technology to deliver personalized mechanical stimulation for hand tremor relief in adults with essential tremor; designed for home healthcare environment use.
Quantifiable outcome
- Device-related adverse events in clinical trials were non-serious and self-resolving
Companies that use Encora Therapeutics
Customer profileSegments1 record
Ideal customer profiles1 record
Encora Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature3 records
Encora Therapeutics partnerships and signals
Strategic signalScale indicators2 records
Recent moves5 records
Expansion highlights5 records
Encora Therapeutics competitors and assessment
Company assessmentBroad incumbents
- Medtronic: Medtronic is the market leader in deep brain stimulation (DBS) systems (Activa) for essential tremor and Parkinson's disease. As the established surgical intervention for medication-refractory essential tremor, Medtronic represents the incumbent treatment pathway that Encora X1 must position against.
- Abbott: Abbott manufactures DBS systems (Infinity, Proclaim) for movement disorders including essential tremor. As a major neuromodulation incumbent, Abbott competes in the same patient population with established reimbursement and deep neurosurgeon relationships.
- Boston Scientific: Boston Scientific offers the Vercise DBS system for Parkinson's and tremor disorders alongside a broader neuromodulation portfolio. As a large medtech with established neurostimulation expertise, it competes for the same movement-disorder neurosurgery patient pool.
- Inspire Medical Systems: Inspire Medical Systems manufactures an implantable hypoglossal nerve stimulation system for obstructive sleep apnea. As a neurostimulation company that scaled from startup to commercial leader, Inspire is a relevant comparable for Encora's commercial trajectory and physician-channel go-to-market model.
Emerging players
- MicroTransponder: MicroTransponder developed the Vivistim system, a vagus nerve stimulation (VNS) device paired with rehabilitation therapy for post-stroke motor recovery. The pairing of neurostimulation with rehabilitation therapy parallels Encora's approach of stimulation for motor symptom management.
- NeuroPace: NeuroPace makes the RNS System, a closed-loop responsive neurostimulation device for refractory epilepsy. While targeting a different indication, NeuroPace shares the closed-loop neurostimulation technology approach with Encora and represents a comparable neurotech commercial-stage business model.
- electroCore: electroCore makes gammaCore, a non-invasive vagus nerve stimulation (nVNS) device for headaches and migraines. As a non-invasive, prescription-based neurostimulation company with established commercial presence in the US, electroCore is a relevant peer for Encora's commercial model and physician-channel distribution.
- Helius Medical Technologies: Helius Medical Technologies developed the Portable Neuromodulation Stimulator (PoNS), a non-invasive neurostimulation device for neurological symptoms. As a non-invasive neurostimulation company, Helius is a comparable peer in technology approach, regulatory pathway, and clinical positioning.
- Axonics: Axonics develops sacral and pudendal neuromodulation systems for incontinence and overactive bladder. As an emerging neuromodulation player that scaled commercially against an entrenched incumbent (Medtronic InterStim), Axonics is a relevant peer model for Encora's commercial scaling dynamics.
Direct peers
- Cala Health: Cala Health makes the Cala Trio, a wrist-worn transcutaneous afferent patterned stimulation (TAPS) therapy device for essential tremor. It is the most direct competitor to Encora X1, offering a non-invasive, wearable, prescription-based neurostimulation for the same indication and patient population.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Encora Therapeutics social profiles
Digital presenceEncora Therapeutics compliance and trust
Trust signalCompliance1 record
Encora Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Encora Therapeutics leadership team
Management profileNumber of profiles
Profiles10 records
Encora Therapeutics funding detail
Funding detailFunding overview
Funding rounds5 records
Investors8 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Encora Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Encora Therapeutics
What does Encora Therapeutics do?
Encora Therapeutics develops and sells the Encora X1, an FDA 510(k)-cleared, non-invasive, wrist-worn wearable neurostimulation device indicated to aid in the relief of hand tremors in adults with essential tremor. The device uses proprietary AI-powered closed-loop technology to perform real-time tremor signal analysis and deliver personalized mechanical stimulation for tremor relief, and is available by prescription only through physician channels in the United States.
Is Encora Therapeutics a public or private company?
Encora Therapeutics is a private company. It is classified as corporate owned and is currently acquired.
When was Encora Therapeutics founded?
Encora Therapeutics was founded in 2018. It employs 1 to 10 people.
Where is Encora Therapeutics based?
Encora Therapeutics is headquartered in Boston, United States, in the North America region.
How does Encora Therapeutics make money?
One revenue line is on record: encora X1 Device Sales.
Who are Encora Therapeutics's main competitors?
Broad incumbents on record are Medtronic, Abbott, Boston Scientific and Inspire Medical Systems. Emerging players are MicroTransponder, NeuroPace, electroCore, Helius Medical Technologies and Axonics. Cala Health is listed as a direct peer.
Does Encora Therapeutics have an API?
No public API is recorded for Encora Therapeutics.
What industry is Encora Therapeutics in?
Encora Therapeutics's product category is Wearable Neurostimulation Medical Devices. Its primary akta.pro industry code is HLAHACAE, Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables), with a secondary code of HLAHAMAG, Rehabilitation Therapy Equipment (PT/OT Modalities, Exercise & Balance Devices). Its NAICS code is 334510 and its SIC code is 3845.